Protherics PLC Notification of PDMR Interests London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 23 November 2007, the following options over ordinary shares of 2 pence each in Protherics ("Ordinary Shares") were granted under the terms of the Company's Long Term Incentive Plan: Name Position Number of Options Ian Scoular Director of Business Development 148,837 Nicholas Staples Director of Corporate Affairs 125,581 Sally Waterman Director of Research & Development 148,837 The options are exercisable at a price of 2 pence per share between the third and tenth anniversary of the date of grant, subject to the achievement of performance conditions. Following the above grant, the total number of options held are as follows: Ian Scoular 1,121,731 Nick Staples 674,744 Sally Waterman 809,210 The current issued ordinary share capital of the Company is 339,696,822 shares. For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113 New York: John Capodanno, Jonathan Birt +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange
Protherics PLC announces Director/PDMR Shareholding - 2
| Source: Protherics PLC
Cheshire, UK--(Marketwire - November 26, 2007) -